Corcept Reports Extended Relacorilant Response in Metastatic Vulvar Cancer
Corcept Therapeutics said a peer-reviewed ESMO Rare Cancers report described a metastatic vulvar cancer patient treated with relacorilant and nab-paclitaxel who remained in response for more than 105 months, or approximately eight years. As of July 2026, the patient was still receiving treatment with stable disease and no new lesions. Corcept cautioned that the observation concerns one patient and may not reflect outcomes across the broader population.
Why it matters
The report adds clinical evidence for relacorilant in metastatic vulvar cancer, an indication outside its current FDA authorization. Because the finding comes from one case, it does not establish the treatment's effectiveness across the wider patient population.
Key facts
- 1The case report appeared in the peer-reviewed journal ESMO Rare Cancers. investing.com
- 2The patient's response duration exceeded 105 months after treatment with relacorilant and nab-paclitaxel. investing.com
- 3By July 2026, the patient remained on treatment with stable disease and no new lesions. investing.com
- 4Relacorilant is FDA-authorized under the name Lifyorli with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.